에 대한 최신 뉴스 TPI Composites (NASDAQ:TPIC) 주식

TPI Composites

TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.

Analyst Color

Government

Large Cap

News

Downgrades

Price Target

Analyst Ratings

Movers

Trading Ideas

General

FSLR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

SEDG

TPIC

최근 미국 대통령 선거 결과, 특히 공화당의 압승은 도널드 트럼프 대통령 당선인의 지도하에 재생 에너지의 미래에 대한 의문을 제기했다. 모건 스탠리의 보고서는 다양한 정책 시나리오에 따른 재생 에너지의 경제적 영향을 평가하고, 이것이 수익성에 미치는 영향을 분석한다.

트럼프의 당선, 경제적 도전으로 인해 재생 에너지 주식의 전망이 암울: 모건 스탠리

TPI Composites Inc

Guidance

GRRR

Gorilla Technology Group Shares Milestone Updates; Set To Enter 2025 With $93M Backlog; Expects Revenue $90M-$100M

Across the recent three months, 14 analysts have shared their insights on Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $11.07, a high estimate of $26.00, and a low estimate of $4.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 30.2%. 
<img src="https://www.benzinga.com/files/images/story/2024/1734375647_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Sage Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sage Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Sage Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sage Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Sage Therapeutics</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Financial Milestones: Sage Therapeutics's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Sage Therapeutics showcased positive performance, achieving a revenue growth rate of 337.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sage Therapeutics's net margin excels beyond industry benchmarks, reaching -788.06%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sage Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -15.86%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sage Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.18%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Sage Therapeutics's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAGE

Where Sage Therapeutics Stands With Analysts

NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $138.33, with a high estimate of $160.00 and a low estimate of $120.00. This current average has increased by 8.6% from the previous average price target of $127.38. 
<img src="https://www.benzinga.com/files/images/story/2024/1734375639_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive NetApp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Karl Ackerman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$132.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$120.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$121.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NetApp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NetApp compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NetApp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of NetApp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NTAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NetApp analyst ratings.</a>
<h2>Discovering NetApp: A Closer Look</h2>
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services.
<h3>NetApp: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: NetApp's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 6.15%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: NetApp's net margin excels beyond industry benchmarks, reaching 18.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): NetApp's ROE stands out, surpassing industry averages. With an impressive ROE of 32.84%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): NetApp's ROA stands out, surpassing industry averages. With an impressive ROA of 3.27%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: NetApp's debt-to-equity ratio surpasses industry norms, standing at 2.52. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTAP

Expert Outlook: NetApp Through The Eyes Of 9 Analysts

Ratings for Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Xometry, presenting an average target of $31.0, a high estimate of $42.00, and a low estimate of $22.00. This upward trend is evident, with the current average reflecting a 15.24% increase from the previous average price target of $26.90.
<img src="https://www.benzinga.com/files/images/story/2024/1734375632_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Xometry among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bruno Montanari</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Greg Palm</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xometry. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xometry compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Xometry's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Xometry's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XMTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Xometry analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Xometry Better</h2>
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of the revenue is earned from the U.S. segment.
<h3>A Deep Dive into Xometry's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Xometry displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 19.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Xometry's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -7.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Xometry's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.23%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.5%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Xometry's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.94.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XMTR

10 Analysts Have This To Say About Xometry

In the last three months, 5 analysts have published ratings on Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $250.4, a high estimate of $275.00, and a low estimate of $227.00. Experiencing a 4.57% decline, the current average is now lower than the previous average price target of $262.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1734375625_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Teleflex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$227.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$255.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teleflex's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teleflex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teleflex analyst ratings.</a>
<h2>Unveiling the Story Behind Teleflex</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>Teleflex: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Teleflex displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 2.41%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.46%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Teleflex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.49%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teleflex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Teleflex Stands With Analysts

Nutanix's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NYSE">NTNX</a>) short percent of float has risen 43.04% since its last report. The company recently reported that it has 7.56 million shares sold short, which is 3.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Nutanix Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734375621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nutanix has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Nutanix's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Nutanix's peer group average for short interest as a percentage of float is 2.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NTNX

Peering Into Nutanix's Recent Short Interest

Analysts' ratings for CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $40.86, a high estimate of $46.00, and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 22.96% increase from the previous average price target of $33.23.
<img src="https://www.benzinga.com/files/images/story/2024/1734375616_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of CarGurus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$46.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.50</td>
<td>$26.50</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CarGurus. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CarGurus compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CarGurus's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CarGurus's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CARG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CarGurus analyst ratings.</a>
<h2>Unveiling the Story Behind CarGurus</h2>
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. The company provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listing through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments namely U.S. Marketplace and Digital Wholesale. It generates majority of revenue from the U.S. Marketplace.
<h3>Unraveling the Financial Story of CarGurus</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: CarGurus's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 5.44%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CarGurus's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.81% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): CarGurus's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: CarGurus's debt-to-equity ratio stands notably higher than the industry average, reaching 0.39. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARG

Assessing CarGurus: Insights From 11 Financial Analysts

Legend Biotech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NYSE">LEGN</a>) short percent of float has risen 3.93% since its last report. The company recently reported that it has 23.81 million shares sold short, which is 24.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 15.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Legend Biotech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734375616_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Legend Biotech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Legend Biotech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Legend Biotech's peer group average for short interest as a percentage of float is 10.92%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LEGN

(LEGN) - Analyzing Legend Biotech's Short Interest

Despite <a href="https://www.benzinga.com/real-estate/24/12/42462666/plan-and-budget-for-the-mid-6-range-what-homebuyers-can-expect-in-2025-according-to-realtor-com#:~:text=Home%20prices%20are%20expected%20to,following%202024's%20projected%204%25%20increase.">high mortgage rates squeezing the national housing market</a>, several Sun Belt cities are set for explosive sales growth in 2025, with Colorado Springs leading an anticipated surge of up to 27% in transaction volume.
The military-heavy Colorado City tops Realtor.com's annual housing forecast, followed by Miami and Virginia Beach, where existing home sales are projected to jump 24% and 23.4%, respectively. These increases dwarf the modest 1.5% growth expected nationwide.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-y2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
</ul>
&#8220;Although affordability is still stretched for many households in these markets, as is the case just about everywhere, aspiring homeowners are able to create opportunities and access homeownership as a result of government-backed loan programs that enable lower down payments,&#8221; Danielle Hale, Realtor.com's chief economist, said in the report.
The forecast heavily favors the South and West, with Texas placing multiple cities in the top rankings. El Paso and McAllen, offering median list prices under $290,000, are projected to increase sales by 19%. According to the report, the Texas markets benefit from military presence, international connections and remote work flexibility.
See Also: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
Local dynamics drive growth in Miami, where sales are expected to surge 24% despite a median list price of $525,000. &#8220;The real estate market buzzes with activity as both locals and international buyers flock to seize the opportunity to invest in this sunny paradise,&#8221; Miami real estate agent Branden Rivero said.
Virginia's strong showing includes Virginia Beach and Richmond in the top five, with projected increases of 23.4% and 21.6%. The coastal region's military concentration – the largest outside the Pentagon – bolsters the market through VA loan accessibility.
Trending: <a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf">&nbsp;</a>
Washington D.C., expecting 17% sales growth, offers an urban alternative to pricier metros. "DC is drawing people in that don't quite want the busyness of New York City but still favor good restaurants, lots of things to do and a top-rated mass transit system," says Cedric Stewart, a Keller Williams real estate expert.
Common threads among the growth markets include recent sales momentum, <a href="https://www.benzinga.com/real-estate/24/12/42312110/more-inventory-should-shake-loose-in-2025-says-zillow-chief-economist">substantial inventory often driven by new construction</a> and demographics skewing younger. Many feature high rates of outright homeownership without mortgage debt, helping buffer against interest rate pressures.
Charlotte is an example of the broad appeal driving the projections. &#8220;The Charlotte market is one of the fastest-growing real estate markets in the country, with over 100 people moving to Charlotte a day,&#8221; Kate Terrigno of Corcoran HM Properties was quoted in the report.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>

Markets

2025's Top Housing Markets: Where Home Sales Will Jump By Up To 27%, According To Report

Western Midstream's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) short percent of float has fallen 3.26% since its last report. The company recently reported that it has 6.18 million shares sold short, which is 3.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Western Midstream Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734375610_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Western Midstream has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Western Midstream's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Western Midstream's peer group average for short interest as a percentage of float is 4.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(WES) - Analyzing Western Midstream's Short Interest

Throughout the last three months, 17 analysts have evaluated C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for C.H. Robinson Worldwide, presenting an average target of $114.82, a high estimate of $140.00, and a low estimate of $85.00. Surpassing the previous average price target of $103.38, the current average has increased by 11.07%.
<img src="https://www.benzinga.com/files/images/story/2024/1734375608_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of C.H. Robinson Worldwide's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Bruce Chan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$112.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jason Seidl</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$119.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$118.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Garrett Holland</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Jordan Alliger</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$107.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jason Seidl</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$113.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$115.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jordan Alliger</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$97.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jonathan Chappell</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to C.H. Robinson Worldwide. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of C.H. Robinson Worldwide compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for C.H. Robinson Worldwide's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into C.H. Robinson Worldwide's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CHRW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on C.H. Robinson Worldwide analyst ratings.</a>
<h2>Discovering C.H. Robinson Worldwide: A Closer Look</h2>
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 61% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (27%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
<h3>C.H. Robinson Worldwide: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: C.H. Robinson Worldwide's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.99%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: C.H. Robinson Worldwide's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.09% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): C.H. Robinson Worldwide's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): C.H. Robinson Worldwide's ROA excels beyond industry benchmarks, reaching 1.75%. This signifies efficient management of assets and strong financial health.
Debt Management: C.H. Robinson Worldwide's debt-to-equity ratio is below the industry average. With a ratio of 1.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHRW

What Analysts Are Saying About C.H. Robinson Worldwide Stock

WIIM

ADUS

Addus HomeCare shares are trading higher. JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $150.

Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) may have bright days thanks to theme parks and streaming, according to Rosenblatt&#8217;s Barton Crockett.
The Disney Analyst: Crockett maintains a Buy rating on Disney and raised the price target from $122 to $135.
The Analyst Takeaways: Disney's growth looks "do-able" and the stock is "buyable," Crockett writes in a new investor note.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
The new $135 price target assumes Disney shares can trade closer to a forward price-to-earnings ratio of 22x, instead of the near 10% discount to the market average Disney stock has traded at in recent history.
"A northward re-rating for Disney can be supported by rising confidence in portfolio durability and growth trajectory, and less concern about exposure to secular pressures on linear TV and competition in streaming," Crockett said.
Disney's confidence in high single-digit earnings per share growth in 2025, and double-digit growth in 2026 and 2027 appears aggressive, Crockett says. But it could become a reality, he adds, after hearing more details from new CFO Hugh Johnson last week.
Disney remains focused on its theme park segment<a href="https://www.benzinga.com/markets/equities/24/12/42382381/disney-doubles-down-on-cruises-with-seven-new-ships-by-2031-targets-asian-market-expansion-best-time-to-invest-in-this-business"> and cruise lines</a>, which will continue to attract guests in future.
Disney's DTC segment, which includes Hulu, Disney+ and ESPN streaming platforms, could also be a key growth element, Crockett said.
The analyst said cross-promotion reduced churn and Disney+ is enjoying a lift in subscribers thanks to several hit films. <a href="https://www.benzinga.com/general/entertainment/24/11/42123085/wicked-gladiator-ii-moana-2-could-break-thanksgiving-weekend-box-office-stocks-to-watch">The release of movies</a> like "Deadpool &amp; Wolverine," "Inside Out 2" and "Moana 2" on Disney+ could help boost subscriber growth ahead.
Crockett says DTC streaming is &#8220;the leading driver of segment profit growth in F2026.&#8221;
Price Action: Disney stock is down 0.58% to $112.41 on Monday versus a 52-week trading range of $83.91 to $123.74. Disney stock is up 24% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42422496/inside-out-2-deadpool-wolverine-baby-reindeer-dominate-entertainment-searches-on-google-in-2024-top-10-movies-tv-shows-and-more">&#8216;Inside Out 2,&#8217; &#8216;Deadpool &amp; Wolverine,&#8217; &#8216;Baby Reindeer&#8217; Google&#8217;s Top 2024 Entertainment Searches</a></li>
</ul>
Image: Shutterstock

Entertainment

Reiteration

Disney Analyst Highlights Streaming, Theme Parks And 'Portfolio Durability'

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) will conduct an investor call on Tuesday to provide full-year 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42415564/pfizer-invites-public-to-view-and-listen-to-webcast-of-december-17-conference-call-with-analysts-t" rel="noreferrer noopener">financial guidance</a>.
Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year.
The analyst anticipates that Pfizer&#8217;s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.
Pfizer highlighted several factors affecting its 2024 EPS that won&#8217;t carry over to 2025.
The 2024 EPS includes one-time boosts: a $1.2 billion benefit <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">from Paxlovid stockpiling</a> and a U.S. government true-up and equity income from its stake in Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>). However, Haleon income will not appear in 2025, as Pfizer&#8217;s ownership in Haleon is <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41112790/pfizer-divests-3-3b-stake-in-sensodyne-toothpaste-and-panadol-painkiller-maker-haleon" rel="noreferrer noopener">dropping below 20%</a>.
Goldman forecasts for 2025 revenues of $64.9 billion and EPS of $3.13, which compares to consensus estimates of $63.2 billion and $2.89, respectively.
Goldman Sachs notes that the impact of the IRA Part D redesign will likely be addressed in the company&#8217;s 2025 guidance. However, the analyst does not expect the details to be broken down by individual products but instead based on the overall commercial portfolio.
The analyst expects Paxlovid sales of $4.3 billion vs. consensus of $3.7 billion, though slightly more conservative on Vyndaqel sales of $5.9 billion vs. consensus of $6.2 billion.
Year-to-date, Eliquis has performed well, showing 12% growth thanks to market expansion and increased market share. This growth has been supported by Pfizer&#8217;s commercial team and boosted by Part D catastrophic coverage in 2024.
Looking ahead to 2025, Pfizer expects continued growth opportunities driven by market expansion and the potential for further share gains.
&#8220;We highlight dynamics across key topics and frame potential points of discussion with potential read-across beyond Pfizer specifically, noting that they are the only large cap pharma company in our coverage that we expect to opine on 2025 ahead of the new year,&#8221; Goldman analyst writes.
Price Action: PFE stock is down 0.39% at $25.48 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507348/ozempic-maker-novo-nordisk-invests-over-1-billion-in-new-production-facility-in-denmark-comes-closer-to-add-three-more-from-catalent" target="_blank" rel="noreferrer noopener">Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent</a></li>
</ul>
Photo via Shutterstock.

Biotech

Earnings

Equities

Health Care

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?

JMP Securities initiated coverage on Addus HomeCare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), a provider of home-based personal care and clinical services.
JMP analysts see Addus HomeCare as having a uniquely strong and well-established presence in personal care services across multiple states, thanks to the company's scale and experienced management team.
The analyst writes that personal care is a cost-effective way to provide home-based services, especially as the U.S. faces a shortage of expensive skilled clinicians.
This approach also helps delay the need for more costly care options. With the highly fragmented personal care sector, Addus has opportunities to expand by adding complementary home health and hospice services to its existing markets.
The analysts expect this strategy to support sustained double-digit revenue growth for the company in the coming years.
In the third quarter, Addus HomeCare revenues were $289.8 million for the third quarter of 2024, a 7.0% increase compared with $270.7 million for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41727154/addus-homecare-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">the third quarter of 2023</a>.
JMP has initiated with a price target of $150, with <a target="_blank" href="https://www.benzinga.com/quote/ADUS/analyst-ratings" rel="noreferrer noopener">a Market Perform rating</a>.
Addus HomeCare recently acquired Gentiva's PC operations. The deal, the largest acquisition in the company's history, is expected to allow Addus HomeCare to enter Texas with critical mass and add personal care services in six other states, three of which are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42276478/addus-homecare-completes-acquisition-of-personal-care-operations-of-gentiva" rel="noreferrer noopener">new to the company</a>.
Gentiva's PC platform is expected to contribute annual revenue of $275 million-$280 million, prompting 29% year-over-year personal care growth for Addus HomeCare in 2025, above the segment's five-year CAGR (2019-2024E) of 8%.
JMP writes that in recent years, Addus HomeCare has expanded into value-based care (VBC) arrangements in select markets through its "Care Advantage" program.
The company is well-positioned to grow in this area thanks to its combination of clinical and non-clinical care resources, along with its large-scale operations and robust case management systems.
Price Action: ADUS stock is up 5.14% at $131.42 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/24/12/42505835/honeywell-advances-strategic-review-explores-aerospace-business-separation" target="_blank" rel="noreferrer noopener">Honeywell Advances Strategic Review, Explores Aerospace Business Separation</a></li>
</ul>
Photo via Shutterstock

Initiation

As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst

<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1200" height="711" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7.png" alt="" class="wp-image-4139" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7-300x178.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7-1024x607.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7-768x455.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Small Language Model</h4>
An enlarged chart of Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of MSFT stock is being used to illustrate the point.</li>
<li>The chart shows MSFT stock has climbed in December so far.</li>
<li>The chart shows support and resistance zones for MSFT.</li>
<li>RSI on the chart shows MSFT stock is overbought.&nbsp; Overbought stocks are susceptible to a pullback.</li>
<li>The Arora Report previously shared with readers a major milestone in AI progress – human-like reasoning capabilities using chain link thinking in Model 4o from OpenAI.</li>
<li>ChatGPT-4o is a large language model.</li>
<li>In further AI progress, Microsoft has introduced Phi-4.&nbsp; Phi-4 is a small language model that outperforms GPT-4o in certain mathematical reasoning.&nbsp; Phi-4 is only a fraction of the size of GPT-4o.&nbsp; It appears that Phi-4 can do better in solving certain math problems compared to its teacher model GPT-4o.&nbsp; Also of note is that Microsoft trained Phi-4 mostly on synthetic data.</li>
<li>The foregoing is important for investors as investors need to get ahead of the curve.&nbsp; In The Arora Report analysis, Phi-4 challenges the present belief that bigger is better.</li>
<li>In The Arora Report analysis, small language models such as Phi-4 have a very bright future.&nbsp; There is a fortune to be made in AI between now and 2030.&nbsp; However, it will not be in a straight line.&nbsp; At times, it will be treacherous.</li>
<li>There is excitement in the stock market this morning as it was announced Friday after the close that AI software company Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and big bitcoin holder MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) are being added to the Nasdaq 100.</li>
<li>The Arora Report has previously written that one of the things Trump can do to reduce inflation from his policies is to attract foreign investment to the U.S.&nbsp; In the first sign of success for Trump, Japan's SoftBank Group Corp &#8211; ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) CEO Masayoshi Son will announce at Mar-a-Largo a $100B investment in the U.S. over the next four years.</li>
<li>There is also buying in the early trade as the market believes it is a certainty that the Fed will cut interest rates this week in spite of the data not supporting such a rate cut.</li>
<li>Markets in the U.S. are not being impacted by weakness in Europe and Asia as there was powerful pumping of stocks in the media over the weekend.&nbsp; Retail investors tend to be influenced by the weekend pump and buy on Monday morning.</li>
</ul>
<h4 class="wp-block-heading">France</h4>
Moody's has cut France's credit rating.&nbsp; French stocks and bonds are falling.
<h4 class="wp-block-heading">China</h4>
Markets all across the globe are being negatively impacted by weak retail sales data in China.
Retail sales in China came at 3.0% year-over-year vs 4.8% consensus.
Concern is building that the Chinese consumer is not spending in spite of stimulus measures by the government.
In The Arora Report analysis, investors should note the sharp contrast between U.S. consumers and Chinese consumers at this time.&nbsp; U.S. consumers are on a buying binge.&nbsp; Chinese consumers are holding back and are focused on savings.
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon.com, Inc., Alphabet Inc Class C , Meta Platforms Inc , NVIDIA Corp , and Tesla Inc.
In the early trade, money flows are neutral in Apple Inc and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.&nbsp; Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.&nbsp; The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).&nbsp; The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).&nbsp; The most popular ETF for oil is United States Oil ETF (ASCA:USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Over the weekend, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ran over $106,000 on a rumor that Trump will announce the bitcoin reserve on day 1.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider holding Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

$BTC

MSFT

MSTR

PLTR

SFTBY

AI Progress From Microsoft – Phi-4 Outperforms Human-like reasoner AI Model GPT-4o, Bitcoin Rumor

Tech stocks extended their rally to new heights on Monday, with the Nasdaq 100 index climbing over 1% to surpass 22,000 points, fueled by robust gains among key <a href="https://www.benzinga.com/tech">components in the index.</a>
Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) led the charge, soaring over 8% after receiving bullish price-target updates from analysts. The company's AI-driven growth potential gained further traction on Friday following its announcement of a collaboration with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to produce a cutting-edge AI chip.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) also rallied, jumping more than 5%, pushing its post-election gains to 85%, buoyed by positive analyst sentiment. Wedbush Securities described Tesla as a &#8220;game-changer&#8221; in AI and autonomous advancements under Trump's administration, adding to the bullish outlook.
Among other indices, the Russell 2000 rose 1%, while the S&amp;P 500 edged up 0.4%. The Dow Jones Industrial Average, however, dipped 0.2%, weighed down by losses in the energy and healthcare sectors.
On the economic front, private-sector surveys showed a stronger-than-expected rebound in December activity. The services sector Purchasing Managers&#8217; Index (PMI) surged to 58.5, the highest reading since October 2021. Meanwhile, the Composite PMI climbed to 56.6, its best level since April 2022, as robust growth in services offset continued weakness in manufacturing.
Crypto-related assets gained fresh bullish momentum, driven by speculation about the U.S. government creating a Bitcoin Strategic Reserve fund. Meanwhile, MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) will be added to the Nasdaq 100 Index on Dec. 23, further boosting sentiment.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reached $107,000, marking a year-to-date gain of 153%. MicroStrategy shares rose 5.8%, while other crypto-linked stocks, such as MARA Digital Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>), Riot Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>), and Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), surged 11.1%, 9.2%, and 4.5%, respectively.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>22,043.82</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,369.39</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,076.94</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,750.42</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121624&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $607.34.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $438.86.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.4% to $537.94.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1% to $235.13.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up by 1.2%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.8%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) rose 7.1%, reflecting bullish investor sentiment ahead of its earnings report on Wednesday after the close.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) rose by 4.7%, building up momentum after last week&#8217;s 8.7% surge following the announcement of the quantum computer launch. </li>
<li>Shares of of natural gas companies fell amid prospects for less colder weather in the upcoming weeks. New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) led industry declines, down 7%. </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">Fed Poised To Cut Interest Rates By 0.25% This Week: Here&#8217;s Why Your Focus Should Shift To Other Signals</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Tech

ETFs

AAPL

AVGO

COIN

SPDR Dow Jones Industrial Average ETF Trust

GOOGL

MARA

RIOT

TSLA

Select Sector SPDR-Consumer Discretionary

Broadcom, Tesla Propel Nasdaq 100 Gains, Bitcoin Hits $107,000, Fueling Crypto Stocks Rally: What's Driving Markets Monday?

CRWD

Crowdstrike shares are trading higher. JP Morgan maintained its Overweight rating on the stock and raised its price target from $372 to $418.

Investors with a lot of money to spend have taken a bearish stance on AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AVAV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for AeroVironment.
This isn't normal.
The overall sentiment of these big-money traders is split between 21% bullish and 42%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $246,086, and 10 are calls, for a total amount of $620,396.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $185.0 for AeroVironment, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of AeroVironment stands at 97.25, with a total volume reaching 519.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AeroVironment, situated within the strike price corridor from $105.0 to $185.0, throughout the last 30 days.
<h3>AeroVironment Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734374730_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVAV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$64.6</td>
<td>$60.9</td>
<td>$62.78</td>
<td>$105.00</td>
<td>$162.7K</td>
<td align="right">0</td>
<td align="right">26</td>
</tr>
<tr>
<td>AVAV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$62.4</td>
<td>$58.8</td>
<td>$60.59</td>
<td>$105.00</td>
<td>$157.0K</td>
<td align="right">50</td>
<td align="right">26</td>
</tr>
<tr>
<td>AVAV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.3</td>
<td>$8.2</td>
<td>$8.2</td>
<td>$165.00</td>
<td>$106.7K</td>
<td align="right">143</td>
<td align="right">130</td>
</tr>
<tr>
<td>AVAV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$26.7</td>
<td>$26.6</td>
<td>$26.6</td>
<td>$185.00</td>
<td>$79.8K</td>
<td align="right">139</td>
<td align="right">51</td>
</tr>
<tr>
<td>AVAV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$12.3</td>
<td>$12.0</td>
<td>$12.01</td>
<td>$160.00</td>
<td>$50.9K</td>
<td align="right">168</td>
<td align="right">84</td>
</tr>
</tbody>
</table>

<h3>About AeroVironment</h3>
AeroVironment Inc operates under a single business segment in which it supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky.
<h3>Where Is AeroVironment Standing Right Now?</h3>
<ul>
<li>With a trading volume of 655,958, the price of AVAV is up by 1.92%, reaching $159.5.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for AeroVironment</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $230.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has elevated its stance to Buy, setting a new price target at $230. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AeroVironment options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

AVAV

What the Options Market Tells Us About AeroVironment

Whales with a lot of money to spend have taken a noticeably bullish stance on Newmont.
Looking at options history for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) we detected 20 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $437,295 and 14, calls, for a total amount of $1,356,261.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $55.0 for Newmont over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Newmont stands at 3573.42, with a total volume reaching 18,285.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Newmont, situated within the strike price corridor from $30.0 to $55.0, throughout the last 30 days.
<h3>Newmont 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734374725_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.42</td>
<td>$2.29</td>
<td>$2.39</td>
<td>$45.00</td>
<td>$358.5K</td>
<td>2.7K</td>
<td>1.5K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.2</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$35.00</td>
<td>$244.2K</td>
<td>631</td>
<td>400</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.25</td>
<td>$1.24</td>
<td>$1.25</td>
<td>$45.00</td>
<td>$237.0K</td>
<td>11.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$0.91</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$35.00</td>
<td>$144.0K</td>
<td>6.7K</td>
<td>1.6K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$3.85</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$45.00</td>
<td>$115.1K</td>
<td>319</td>
<td>300</td>
</tr>
</tbody>
</table>

<h3>About Newmont</h3>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
Following our analysis of the options activities associated with Newmont, we pivot to a closer look at the company's own performance.
<h3>Current Position of Newmont</h3>
<ul>
<li>With a trading volume of 4,814,346, the price of NEM is down by -0.29%, reaching $40.1.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Newmont, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on NEM Options

TPI Composites, Inc. (TPIC) Q3 2024 Earnings Call Transcript

Citi predicts pressure on oil prices in 2025 under second Trump presidency

Warning: TPIC is at high risk of performing badly

Morgan Stanley analyst Andrew Percoco downgraded TPI Composites (TPIC) to Underweight from Equal Weight with a price target of $2, down from $4. Pu...

TPI Composites downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley downgraded TPI Composites (TPIC) to Underweight from Equal Weight with a price target of $2, down from $4. The firm also reduced its...

Morgan Stanley cuts TPI Composites to Underweight on prolonged recovery

SolarEdge, Maxeon Solar slammed as Morgan Stanley cuts to Sell equivalent

Biden pushes ahead with methane fee despite Trump's win, asks E.U. to align with U.S.

Stifel Nicolaus analyst Stephen Gengaro maintained a Hold rating on TPI Composites (TPIC – Research Report) yesterday and set a price target of $3....

TPI Composites (TPIC) Gets a Hold from Stifel Nicolaus

JPMorgan downgraded TPI Composites (TPIC) to Neutral from Overweight without a price target Although JPMorgan continues to expect a "significant ra...

TPI Composites downgraded to Neutral from Overweight at JPMorgan

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Meta donates $1M to President-elect's inaugural fund

ACES

AMPS

AMRC

AMTX

BOIL

CMCL

CNRG

DRIP

EOSE

EQIX

ERTH

GTLS

GUSH

HNRG

ICLN

INDO

KLXE

KOLD

LICY

LTBR

NPWR

OKLO

PEGY

PLUG

PPTA

PRIM

QCLN

REPX

SMOG

STLD

USAU

USOI

VSTE

Press Releases

TPI Composites, Inc. Announces First Quarter 2024 Earnings Results – Results In-line with Company Expectations; Reiterate Full Year 2024 Financial Guidance

TPI Composites Partners with University of Maine and Oak Ridge National Laboratory to Leverage One of the World's Largest Polymer 3D Printers for Wind Turbine Tooling

TPI Composites Manufactures All-Composite Cab for the Next-Generation Kenworth SuperTruck 2

Contracts

TPI Composites Announces Agreement to Divest Automotive Business Unit as a Part of Continued Focus on Wind

TPI Composites, Inc. Announces Second Quarter 2024 Earnings Release Date and Conference Call

TPI Composites, Inc. Announces Second Quarter 2024 Earnings Results – Remains Well Positioned for a Recovery in the Second Half of 2024

TPI Composites Participates in Cure Optimization for Wind Blade Fabrication with University of Texas at Dallas

TPI Composites, Inc. Announces Third Quarter 2024 Earnings Release Date and Conference Call

Management

Jennifer Lowry to Join the Board of Directors of TPI Composites, Inc.

TPI Composites, Inc. Announces Third Quarter 2024 Earnings Results – Operational Execution and Strategic Initiatives Drive Improved Profitability

CWEN

MYRG

Bloom Energy Corporation Class A Common Stock

Bloom Energy

Babcock & Wilcox Enterprises, Inc. Common Stock

Babcock & Wilcox

Broadwind

Clean Energy Technologies, Inc. - Common Stock

Clean Energy Technologies

GE Vernova

Nano Nuclear Energy

NET Power

Energy Vault Holdings

Ocean Power Technologies, Inc. Common Stock

Ocean Power Techs

Polar Power

Pioneer Power Solutions, Inc. - Common Stock

Pioneer Power Solutions

NuScale Power Corporation Class A Common Stock

NuScale Power

Morgan Stanley

B of A Securities

Jefferies

Piper Sandler

Roth MKM

최근 미국 대통령 선거 결과, 특히 공화당의 압승은 도널드 트럼프 대통령 당선인의 지도하에 재생 에너지의 미래에 대한 의문을 제기했다.
모건 스탠리의 보고서는 다양한 정책 시나리오에 따른 재생 에너지의 경제적 영향을 평가하고, 이것이 수익성에 미치는 영향을 분석한다.
이 애널리스트는 청정 기술 산업에 대한 전망을 &#8220;매력적&#8221;에서 &#8220;중립&#8221;으로 조정했다.
추가 읽기: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41880110/solar-renewables-stocks-crash-after-trump-win-should-you-buy-now-at-cheap-valuations" target="_blank" rel="noreferrer noopener">트럼프 승리 후 태양광 및 재생 에너지 주식 폭락: 지금 저렴한 가치에서 사야 할까?</a>
장기적으로 재생 에너지에 대한 수요는 현재 시장의 인식보다 강할 가능성이 높지만, 새로운 불확실성으로 인해 단기 성장 전망은 덜 확실해졌다.
이러한 새로운 불확실성은 청정 에너지 부문이 직면하고 있는 이미 어려운 환경에 추가된다. 여기에는 허가 및 연결 지연 문제, 자금 조달 문제 및 수익성을 해친 치열한 경쟁 등이 포함된다.
인플레이션 감축법(IRA), 관세 및 금리에 대한 불확실성은 청정 연료 평가에 상당한 영향을 미쳤다.
모건 스탠리는 청정 기술 평가가 반등하기 위해서는 IRA에 대한 명확한 가이드가 필수적이라고 작성했다. 그러나 이는 2025년 말에 만료될 예정인 감세 및 일자리 법안(TCJA)에 대한 논의와 연결될 가능성이 높기 때문에 시간이 걸릴 수 있다.
모건 스탠리는 고품질 및 내구성 있는 성장/마진을 가진 주식에 투자할 것을 추천하며, 명확한 촉매 경로 및/또는 강력한 재무 상태를 통해 단기적인 성장 및/또는 수익성의 변동성을 견딜 수 있어야 한다.
<ul>
<li>애널리스트는 GE 버노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), 퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) 그리고 블룸 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>)에 대해 비중확대 등급을 유지했다.</li>
</ul>
그러나 이 애널리스트는 세 가지 청정 기술 주식을 중립에서 비중 축소로 하향 조정했다:
<ul>
<li>솔라엣지 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>): 애널리스트는 유럽 수요 감소와 저가 중국 제조업체와의 치열한 경쟁으로 인한 수익성 둔화를 이유로 목표 주가를 $23에서 $9로 하향 조정했다. 결과적으로, 회사는 <a href="https://www.benzinga.com/quote/SEDG/analyst-ratings" target="_blank" rel="noreferrer noopener">2026년 이후</a>에 EBITDA에서 손익 분기점에 도달할 것으로 예상되지 않는다. 금요일 주가는 17.07% 급락한 $10.64로 마감했다. 지난 5일 동안 21.76% 하락했다.</li>
<li>맥시온 솔라 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>): 모건 스탠리는 유럽의 유틸리티 규모 태양광 시장에서의 경쟁 증가로 인해 수익성이 느리게 회복될 것으로 예상하여 <a href="https://www.benzinga.com/quote/MAXN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 가격을 $4</a>로 유지하고 있다. 또한 최근 미국 주택 시장에서 고객 손실로 인해 시장 점유율과 프리미엄 가격 유지가 어려워질 수 있다. 금요일 주가는 13.22% 급락한 $9.98로 마감했다. 지난 5일 동안 2.16% 하락했다.</li>
<li>TPI 컴포지트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>): 애널리스트는 미국 풍력 시장이 얼마나 빨리 회복될지에 대한 불확실성을 언급했다. 이는 자금 조달 확보 문제와 산업이 더 큰 블레이드 크기로 전환됨에 따른 설계 및 검사 문제로 인해 발생한다. 모건 스탠리는 <a href="https://www.benzinga.com/quote/TPIC/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $4에서 $2로</a> 하향 조정했다. 금요일 주가는 8.82% 하락한 $2.16로 마감했다. 지난 5일 동안 23.59% 하락했다.</li>
</ul>
 
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42012689/life-insurance-firm-aegon-trades-higher-as-capital-ratios-remain-solid" target="_blank" rel="noreferrer noopener">아혼 생명 보험 회사, 자본 비율이 안정적으로 유지됨에 따라 상승 거래</a></li>
</ul>
사진 출처: Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

TPI Composites

뉴스

에 대한 최신 뉴스 TPI Composites (NASDAQ:TPIC) 주식

토요일, 11월 16, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌